Standard Treatment

ApprovedSmall molecule

Boehringer Ingelheim

Standard Treatment is one of 703 small molecule programs targeting Hepatic failure. It is currently in Approved.

Indications

Total Trials

Active Trials

702

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatic FailureActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Cardiac ArrestActive, not recruiting

PoisoningActive, not recruiting

HypoxemiaActive, not recruiting

IschemiaActive, not recruiting

HyperthyroidismActive, not recruiting

MucositisActive, not recruiting

Pulmonary HypertensionActive, not recruiting

SepsisActive, not recruiting

Hepatic FailureApproved

Active, not recruiting

Cardiovascular DiseaseApproved

Active, not recruiting

Cardiac ArrestPhase 2

Active, not recruiting

PoisoningPhase 1

Active, not recruiting

HypoxemiaPhase 2/Phase 3

Active, not recruiting

IschemiaApproved

Active, not recruiting

HyperthyroidismPhase 3

Active, not recruiting

MucositisPhase 2

Active, not recruiting

Pulmonary HypertensionPreclinical

Active, not recruiting

SepsisPhase 2/Phase 3

Active, not recruiting

Showing 10 of 27 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Standard Treatment

Boehringer Ingelheim

Approved

1 2

Halaven

Eisai

Preclinical

38 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—8

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 9

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 10

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Post-ApprovalRecruiting

Percutaneous Coronary Intervention

NCT03378934

Q1 2027

Post-ApprovalRecruiting

Biomarkers

NCT07314684

Q2 2027

Phase 3Not yet recruiting

Small Cell Lung Cancer

NCT06961201

Q3 2027

Phase 1/2Recruiting

Advanced or Metastatic Solid Tumors

NCT07035249

Phase 2Recruiting

Mycobacterium

NCT06585020

Clinical

Trials by Indication[1]

COVID-194 trials

Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)

Unknown status·KKafrelsheikh University·Phase 3·NCT04353180·100,000 enrolled

Colchicine Plus Phenolic Monoterpenes to Treat COVID-19

Completed·KKermanshah University of Medical Sciences·Phase 1/2·NCT04392141·120 enrolled

Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19

Unknown status·—·N/A·NCT04463420·224 enrolled

Show 1 more trial

Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial

Unknown status·HHamad Medical Corporation·Phase 4·NCT04445935·100 enrolled

Poisoning2 trials

The Role of N-acetylcysteine as a Novel Adjuvant Treatment in Acute Organophosphorus Pesticide Poisoning

Completed·—·Phase 1·NCT05927259·40 enrolled

Paraffin Oil or Coconut Oil in Acute Aluminum Phosphide Poisoning

Completed·TTanta University·Phase 1·NCT04724655·89 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILI

Completed·—·Phase 1/2·NCT02651350·80 enrolled

The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI

Unknown status·PPeking University Third Hospital·Phase 4·NCT05511831·60 enrolled

Treatment2 trials

Use of Alfuzosin in Stone Treatment With ESWL

Withdrawn·SSingapore General Hospital·Phase 3·NCT00388271

Intensive Insulin Treatment and Ischemic Foot Ulcer

Completed·KKarolinska Institutet·N/A·NCT01957930·91 enrolled

Heart Failure2 trials

GOREISAN for Heart Failure (GOREISAN-HF) Trial

Active, not recruiting·TTakeshi Morimoto·Phase 4·NCT04691700·1,179 enrolled

Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)

Active, not recruiting·—·Phase 4·NCT05164653·400 enrolled

37 more indications

Heart Disease2 trials

Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT01396395·402 enrolled

Fastigial Nucleus Stimulation for Coronary Heart Disease

Unknown status·—·N/A·NCT04121715·200 enrolled

Cardiovascular Disease1 trial

Traditional Chinese Medicine Intervention for Ischemic Cardiovascular Disease Comorbid With Diabetes Mellitus: An Efficacy Comparative Study

Not yet recruiting·GGuangzhou University of Traditional Chinese Medicine·Phase 4·NCT07088523·4,205 enrolled

Advanced or Metastatic Solid Tumors1 trial

DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors

Recruiting·WWest China Hospital·Phase 1/2·NCT07035249·9 enrolled

GvHD1 trial

Ruxolitinib In GvHD

Terminated·PProf. Dr. Nikolas von Bubnoff·Phase 2·NCT02396628·22 enrolled

Parkinson1 trial

Cilostazol in Parkinson's Disease

Not yet recruiting·—·Phase 2·NCT06612593·50 enrolled

Cirrhosis1 trial

Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.

Withdrawn·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02868164

Acute Lymphoblastic Leukemia1 trial

Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol

Unknown status·VVastra Gotaland Region·Phase 2·NCT03022747·60 enrolled

Hepatic failure1 trial

RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure

Unknown status·—·Phase 4·NCT02331745·140 enrolled

Hospitalized Patients1 trial

Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19

Completed·IInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz·Phase 4·NCT04392531·111 enrolled

Rheumatoid Arthritis1 trial

Effectiveness of Probiotics in Patients of Mild to Moderate Rheumatoid Arthritis

Completed·KKing Edward Medical University·Phase 3·NCT06594822·88 enrolled

Migraine1 trial

Low-dose Propofol for Pediatric Migraine

Completed·OOregon Health and Science University·Phase 2/3·NCT01604785·74 enrolled

Percutaneous Coronary Intervention1 trial

Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention

Recruiting·PPeking Union Medical College Hospital·Phase 4·NCT03378934·64 enrolled

Chronic Rhinosinusitis1 trial

Nigella Sativa for Selected Outcomes in Chronic Rhinosinusitis

Completed·—·N/A·NCT05494164·102 enrolled

Renal Cell Carcinoma1 trial

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

Terminated·AArgos Therapeutics·Phase 3·NCT01582672·462 enrolled

Breast Cancer1 trial

Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00024102·633 enrolled

Knee Surgery1 trial

Ear Acupuncture for Pain Associated With Ambulatory Arthroscopic Knee Surgery

Completed·MMike O'Callaghan Military Hospital·N/A·NCT01447329·49 enrolled

Biomarkers1 trial

GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM

Recruiting·FFederico II University·Phase 4·NCT07314684·80 enrolled

Mucositis1 trial

Local Anesthetic Treatment of Oral Pain in Patients With Mucositis

Completed·HHvidovre University Hospital·Phase 2·NCT02252926·70 enrolled

Ewing sarcoma1 trial

Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma

Completed·IItalian Sarcoma Group·Phase 3·NCT02063022·278 enrolled

Smoking Cessation1 trial

Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation

Completed·UUniversity of Pennsylvania·Phase 3·NCT00364156·568 enrolled

Plantar Fasciopathy1 trial

Early Intervention With Therapeutic Exercise in Plantar Fasciopathy

Not yet recruiting·UUniversidad Miguel Hernandez de Elche·N/A·NCT06394336·60 enrolled

Premature Ejaculation1 trial

Effectiveness and Safety of TENS Therapy for Premature Ejaculation

Recruiting·BBoston Medical Group·Phase 3·NCT06425224·129 enrolled

Ischemia1 trial

Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb)

Completed·FFadoi Foundation, Italy·Phase 4·NCT01718288·150 enrolled

Pulmonary Tuberculosis1 trial

Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081

Completed·SShanghai Jiatan Pharmatech Co., Ltd·Phase 2·NCT04608955·99 enrolled

Osteoarthritis1 trial

Effectiveness and Safety of Synvisc® Versus Usual Treatments in Patients With Knee Osteoarthritis

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02197026·518 enrolled

Hyperthyroidism1 trial

Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism

Unknown status·—·Phase 3·NCT03303053·135 enrolled

Small Cell Lung Cancer1 trial

Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase

Not yet recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 3·NCT06961201·94 enrolled

Mycobacterium1 trial

Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection

Recruiting·—·Phase 2·NCT06585020·190 enrolled

Sepsis1 trial

Effect of Montelukast Versus Co Enzyme in Sepsis

Completed·—·Phase 2/3·NCT05293132·90 enrolled

Complication1 trial

The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention

Terminated·NNational and Kapodistrian University of Athens·Phase 2·NCT04326790·105 enrolled

Trial1 trial

Glycemia in Diabetic Elders Trial

Terminated·JJohns Hopkins University·Phase 4·NCT02029846·2 enrolled

Virtual Reality1 trial

Virtual Reality MObility for Burn Patients

Unknown status·SSt. Justine's Hospital·N/A·NCT04538573·20 enrolled

Pulmonary Hypertension1 trial

Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure

Completed·NNanjing First Hospital, Nanjing Medical University·N/A·NCT02220335·98 enrolled

Hypoxemia1 trial

Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia

Completed·IIstanbul University·Phase 2/3·NCT04990830·80 enrolled

Cardiac Arrest1 trial

Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.

Recruiting·—·Phase 2·NCT05817851·234 enrolled

Severe Poisoning With Cardiotropic or Psychotropic Drug1 trial

Reduction of Digestive Absorption of Toxic Substances by Combined Digestive Decontamination in Intensive Care - Randomized Single-center Study

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT07201311·200 enrolled

Unspecified5 trials

OUT-OF-HOSPITAL CPAP STUDY

Completed·UUniversity Hospital, Toulouse·Phase 4·NCT00439075·124 enrolled

Prognostic Predictors of Response to Hypoglycemic Therapy

Unknown status·FFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health·Phase 4·NCT03804411·800 enrolled

Direct Peritoneal Resuscitation Plus Conventional Resuscitation

Withdrawn·UUniversity of Louisville·Phase 4·NCT01882218

Show 2 more trials

The Effect of Naftopidil for the Double-J Stent Discomfort

Completed·SSeoul National University Hospital·Phase 3·NCT01959074·100 enrolled

Medical Expulsive Therapy for Ureter Stone Using Naftopidil

Completed·SSeoul National University Hospital·Phase 3·NCT01952314·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 54 trial records for Standard Treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard Treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard Treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

Standard Treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

COVID-194 trials

Poisoning2 trials

Efficacy and Safety2 trials

Treatment2 trials

Heart Failure2 trials

Heart Disease2 trials

Cardiovascular Disease1 trial

Advanced or Metastatic Solid Tumors1 trial

GvHD1 trial

Parkinson1 trial

Cirrhosis1 trial

Acute Lymphoblastic Leukemia1 trial

Hepatic failure1 trial

Hospitalized Patients1 trial

Rheumatoid Arthritis1 trial

Migraine1 trial

Percutaneous Coronary Intervention1 trial

Chronic Rhinosinusitis1 trial

Renal Cell Carcinoma1 trial

Breast Cancer1 trial

Knee Surgery1 trial

Biomarkers1 trial

Mucositis1 trial

Ewing sarcoma1 trial

Smoking Cessation1 trial

Plantar Fasciopathy1 trial

Premature Ejaculation1 trial

Ischemia1 trial

Pulmonary Tuberculosis1 trial

Osteoarthritis1 trial

Hyperthyroidism1 trial

Small Cell Lung Cancer1 trial

Mycobacterium1 trial

Sepsis1 trial

Complication1 trial

Trial1 trial

Virtual Reality1 trial

Pulmonary Hypertension1 trial

Hypoxemia1 trial

Cardiac Arrest1 trial

Severe Poisoning With Cardiotropic or Psychotropic Drug1 trial

Unspecified5 trials

References

Drug Info

Quick Facts

Related News